6:27 PM
 | 
Oct 27, 2008
 |  BC Extra  |  Clinical News

ZymoGenetics down on stopped lupus trial

ZymoGenetics (NASDAQ:ZGEN) fell $1.42 (29%) to $3.53 on Monday after disclosing in an SEC filing that partner Merck KGaA (Xetra:MRK) stopped a Phase II/III trial of atacicept to treat active lupus nephritis. According to...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >